Topics:
Breast Cancer • Medical Oncology
How do you decide on the type of ovarian suppression (GnRH agonist vs. GnRH antagonist) in premenopausal patients treated with an AI?
In obese patients, would it make sense to switch from a GnRH agonist to an antagonist based on the data from the recent JCO study of dagrelix vs. triptorelin (Dellapasqua S et al. JCO 2019)
Answer from: Medical Oncologist at Academic Institution
Based on current available literature in Breast Cancer it is premature to change to GnRH antagonist such as Degarelix. While action of onset is more rapid with Degarelix (3 days) versus triptorelin (14days) (GnRH agonist) side effects are more pronounced and efficacy data is still lacking.
In the r...
Sign in or Register to read more